Review synthesizes 2025 advances in heart failure treatment, highlighting **tirzepatide** and novel devices

Heart failure (HF) remains a leading global cause of morbidity and mortality, affecting 1-3% of the population. Despite the efficacy of guideline-directed medical therapy (GDMT), patients still experience high rates of rehospitalization and mortality. Current treatments often focus on neurohumoral modulation, leaving a gap in addressing the intrinsic biological processes driving HF progression. This necessitates continuous research into novel therapeutic strategies and an updated understanding of the evolving treatment landscape.

This review systematically synthesizes landmark research and clinical progress in Heart Failure from 2025. It covers epidemiological trends, causes, risk factors, and treatments, drawing from recent large-scale clinical trials such as the DAPA ACT HF-TIMI 68 trial and the VICTOR trial. The authors also integrated insights from emerging pharmacotherapies, device-based therapies (e.g., preCARDIA, CRT-D), and cutting-edge approaches like stem cell therapy, aiming to provide a timely update for clinical practice.

Significant progress was noted across several therapeutic domains for Heart Failure. Pharmacotherapy saw advancements with agents like finerenone and tirzepatide, offering new options for clinicians. Device-based therapies, including preCARDIA and cardiac resynchronization therapy with defibrillator (CRT-D), were highlighted for their evolving role. The completion of large-scale clinical trials, specifically the DAPA ACT HF-TIMI 68 and VICTOR trials, provided solid evidence that is expected to drive changes in clinical practice. Novel devices were identified as promising alternatives and supplements to conventional treatments. > Additionally, cutting-edge therapies such as stem cell therapy revealed promising clinical prospects, indicating potential future directions for HF management.